Promis Neurosciences (PMN) to Release Earnings on Monday

Promis Neurosciences (NASDAQ:PMN) is anticipated to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Promis Neurosciences to post earnings of ($4.22) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 30, 2026 at 9:30 AM ET.

Promis Neurosciences Trading Down 3.3%

Shares of NASDAQ PMN opened at $17.60 on Monday. The stock has a fifty day moving average price of $15.59 and a 200 day moving average price of $11.79. Promis Neurosciences has a 12-month low of $6.27 and a 12-month high of $39.75. The company has a market cap of $37.88 million, a P/E ratio of -0.93 and a beta of -0.23.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on PMN shares. Guggenheim decreased their target price on Promis Neurosciences from $125.00 to $35.00 and set a “buy” rating for the company in a research report on Friday, February 6th. HC Wainwright reiterated a “buy” rating and set a $18.00 target price (up from $4.00) on shares of Promis Neurosciences in a report on Monday, December 1st. Wall Street Zen lowered Promis Neurosciences to a “strong sell” rating in a research report on Saturday, February 14th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Promis Neurosciences in a report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.67.

Insiders Place Their Bets

In other Promis Neurosciences news, insider Johanne Kaplan acquired 1,629 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were bought at an average cost of $15.35 per share, for a total transaction of $25,005.15. Following the acquisition, the insider directly owned 3,941 shares of the company’s stock, valued at $60,494.35. This trade represents a 70.46% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Eugene Williams bought 2,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was acquired at an average cost of $24.00 per share, for a total transaction of $48,000.00. Following the completion of the transaction, the director owned 12,397 shares in the company, valued at $297,528. This represents a 19.24% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 705,370 shares of company stock worth $8,595,523 in the last three months. 3.80% of the stock is owned by insiders.

Institutional Trading of Promis Neurosciences

A hedge fund recently raised its stake in Promis Neurosciences stock. Citadel Advisors LLC raised its stake in shares of Promis Neurosciences (NASDAQ:PMN) by 168.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 170,079 shares of the company’s stock after acquiring an additional 106,650 shares during the quarter. Citadel Advisors LLC owned approximately 0.32% of Promis Neurosciences worth $72,000 at the end of the most recent quarter. Institutional investors and hedge funds own 50.13% of the company’s stock.

Promis Neurosciences Company Profile

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.